Pluri (PLUR) Competitors $4.68 +0.17 (+3.66%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR vs. KRRO, ACRS, FATE, EPRX, IKT, GLSI, PLX, TARA, SLN, and FTLFShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Korro Bio (KRRO), Aclaris Therapeutics (ACRS), Fate Therapeutics (FATE), Eupraxia Pharmaceuticals (EPRX), Inhibikase Therapeutics (IKT), Greenwich LifeSciences (GLSI), Protalix BioTherapeutics (PLX), Protara Therapeutics (TARA), Silence Therapeutics (SLN), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Korro Bio Aclaris Therapeutics Fate Therapeutics Eupraxia Pharmaceuticals Inhibikase Therapeutics Greenwich LifeSciences Protalix BioTherapeutics Protara Therapeutics Silence Therapeutics FitLife Brands Korro Bio (NASDAQ:KRRO) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk. Do institutionals & insiders believe in KRRO or PLUR? 13.2% of Korro Bio shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 4.6% of Korro Bio shares are held by company insiders. Comparatively, 10.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is KRRO or PLUR more profitable? Korro Bio has a net margin of 0.00% compared to Pluri's net margin of -3,551.49%. Korro Bio's return on equity of -50.25% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Korro BioN/A -50.25% -38.48% Pluri -3,551.49%-2,778.13%-83.61% Does the media prefer KRRO or PLUR? In the previous week, Korro Bio had 4 more articles in the media than Pluri. MarketBeat recorded 7 mentions for Korro Bio and 3 mentions for Pluri. Korro Bio's average media sentiment score of 0.59 beat Pluri's score of 0.42 indicating that Korro Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pluri 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer KRRO or PLUR? Korro Bio received 32 more outperform votes than Pluri when rated by MarketBeat users. CompanyUnderperformOutperformKorro BioOutperform Votes32100.00% Underperform VotesNo VotesPluriN/AN/A Which has more risk and volatility, KRRO or PLUR? Korro Bio has a beta of 2.66, suggesting that its share price is 166% more volatile than the S&P 500. Comparatively, Pluri has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Do analysts prefer KRRO or PLUR? Korro Bio currently has a consensus target price of $102.43, suggesting a potential upside of 591.62%. Given Korro Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Korro Bio is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Pluri 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, KRRO or PLUR? Pluri has lower revenue, but higher earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKorro Bio$4.82M28.85-$81.17M-$9.44-1.57Pluri$1.03M34.09-$20.89M-$5.53-0.81 SummaryKorro Bio beats Pluri on 12 of the 18 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.25M$2.93B$5.33B$8.39BDividend YieldN/A1.68%5.21%4.11%P/E Ratio-0.8031.1826.7119.71Price / Sales34.09398.76386.12120.59Price / CashN/A168.6838.2534.62Price / Book-10.713.236.774.50Net Income-$20.89M-$72.35M$3.23B$248.22M7 Day Performance-10.71%5.01%1.80%0.56%1 Month Performance-6.25%5.63%11.10%13.17%1 Year Performance-26.35%-27.04%17.11%7.30% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri0.4157 of 5 stars$4.50-0.2%N/A-25.8%$35.25M$1.03M-0.80150Gap UpKRROKorro Bio2.0095 of 5 stars$15.71+4.0%$102.43+552.0%-70.9%$147.53M$4.82M-1.6670Analyst RevisionGap UpACRSAclaris Therapeutics2.8704 of 5 stars$1.30-0.8%$10.00+669.2%+9.3%$140.77M$17.78M-2.50100Positive NewsFATEFate Therapeutics4.3437 of 5 stars$1.22+14.0%$4.14+239.6%-68.4%$139.82M$13.34M-0.74550EPRXEupraxia Pharmaceuticals2.1352 of 5 stars$3.90+1.6%$10.50+169.2%+32.3%$139.81MN/A-5.4229Gap UpIKTInhibikase Therapeutics1.5119 of 5 stars$1.87-7.0%$6.50+247.6%+4.2%$139.02M$260,000.00-0.706GLSIGreenwich LifeSciences1.2048 of 5 stars$10.18+4.5%$39.00+283.1%-28.1%$135.13MN/A-12.723Negative NewsEarnings ReportPLXProtalix BioTherapeutics2.1877 of 5 stars$1.68+0.6%$15.00+792.9%+40.2%$132.94M$59.76M-12.92200TARAProtara Therapeutics2.9944 of 5 stars$3.42+7.2%$20.40+496.5%+10.9%$131.95MN/A-1.2130News CoveragePositive NewsAnalyst ForecastGap UpSLNSilence Therapeutics3.5193 of 5 stars$4.96+13.5%$33.83+582.1%-78.5%$130.79M$27.70M-3.16100Positive NewsFTLFFitLife Brands4.4223 of 5 stars$13.79+1.1%$20.50+48.7%+0.0%$129.41M$64.47M16.3220Earnings ReportAnalyst DowngradeGap Up Related Companies and Tools Related Companies Korro Bio Competitors Aclaris Therapeutics Competitors Fate Therapeutics Competitors Eupraxia Pharmaceuticals Competitors Inhibikase Therapeutics Competitors Greenwich LifeSciences Competitors Protalix BioTherapeutics Competitors Protara Therapeutics Competitors Silence Therapeutics Competitors FitLife Brands Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLUR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PLUR Stock Free PLUR Stock Alerts